The expanding population of immunocompromised patients seen over the last decade has resulted in an increased incidence of opportunistic mycoses. Immune deficiencies resulting from AIDS, organ transplants, immunosuppressant chemotherapy, and other iatrogenic or nosocomial situations have predisposed an increasing segment of the population to these infections and have created a critical need for new, safe, fungicidal agents that can be used to treat these life-threatening, disseminated diseases. Since diagnosis of suspected fungal infections is often unpredictive or delayed because of the nature of the diagnostic techniques that are used, current therapy is frequently initiated empirically and still relies on amphotericin B (AMB) as the drug of choice because of its broad-spectrum and fungicidal activity. However, AMB is relatively toxic, and its clinical utility is limited to controlled intravenous (i.v.) administration and thus is used primarily to treat deep-seated fungal infections (13, 21) . The newer azole antifungal agents have broad spectra of activity, are orally active, and are considered to be less toxic than AMB but are fungistatic against most major fungal pathogens (21) .
The pneumocandins (lipopeptides) are cyclic hexapeptides with fatty acyl side chains similar in structure to the echinocandin class of antifungal agents (2, 8) . Previously reported pneumocandins have been shown to be fungicidal in vitro and to have an antifungal spectrum limited mainly to Candida species (3, 4) . In vivo efficacy has been reported in animal models of disseminated candidiasis (4, 5) , oropharyngeal and gastrointestinal candidiases (12) , and Pneumocystis carinii pneumonia (3, 26, 27) . The term ''pneumocandin'' has been coined from the anti-P. carinii and anti-Candida activities that these compounds possess (13, 28) . The pneumocandins are inhibitors of 1,3-␤-D-glucan synthesis, a critical structural cell wall component in certain pathogenic fungi and P. carinii cysts (2, 4, 8, 19, 20) . In the study described in this report, the in vivo activities of the water-soluble pneumocandin derivatives L-733560, L-731373, and L-705589 were evaluated in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis.
MATERIALS AND METHODS
Drugs. The pneumocandins L-733560, L-705589, and L-731373 were synthesized by the Department of Synthetic Chemical Research at Merck Research Laboratories, Rahway, N.J. The pneumocandins and fluconazole (FCZ; Pfizer, Groton, Conn.) were formulated in sterile distilled water. Itraconazole (ITZ), which was received from Janssen (Beerse, Belgium), was suspended and diluted in aqueous vehicle (AV) solution (Merck & Co., West Point, Pa.). AV solution consists of 0.9% sodium chloride, 0.5% carboxymethyl cellulose, 0.4% Tween 80, and 0.9% benzyl alcohol. Ketoconazole (KTZ; Janssen) was solubilized in 0.2 N HCl. AMB was purchased as Fungizone (E. R. Squibb & Sons, Princeton, N.J.) and was reconstituted according to the manufacturer's instructions and diluted in sterile water.
Animals. Outbred, female CD-1 mice (average weight, 19 to 21 g; Charles River, Wilmington, Mass.) were used in the disseminated candidiasis survival studies. Complement component CЈ5-deficient DBA/2N female mice (average weight, 19 to 21 g; Taconic Farms, Germantown, N.Y.) were used in the disseminated aspergillosis and candidiasis survival studies and in the Candida and Cryptococcus target organ assays because they have previously been shown to be highly susceptible to fungal infections (16 7 blastoconidia per mouse; these inocula were previously determined to represent one 14-day 100% lethal dose for each strain of mouse.
Therapy was initiated within 15 to 30 min after challenge, and mice were treated for a total of 4 days in the candidiasis model and 5 days in the aspergillosis model. The pneumocandins were administered intraperitoneally (i. Target organ studies. DBA/2N mice were infected i.v. with approximately one 50% lethal dose of C. albicans MY1055 (7.5 ϫ 10 4 blastocondia per mouse) or C. neoformans MY2061 (1 ϫ 10 6 cells per mouse). Therapy was initiated within 15 to 30 min after challenge, and mice were treated for a total of 4 days. Compounds were administered as described above. The target organ assay for C. albicans monitors the number of CFU per gram of paired kidneys at time points following challenge (target organ kidney assay [TOKA] ). The target organ assay for C. neoformans monitors the number of CFU per gram of brain and spleen at time points following challenge (target organ brain and spleen assay). Organs from sacrificed mice (five mice per group per experiment) were removed by using aseptic technique, weighed, and placed in sterile Whirl Pak bags (Fisher Scientific) containing 5 ml of sterile saline. The organs were homogenized in the bags and were serially diluted in saline, and aliquots were plated onto SDA plates. The plates were incubated at 35ЊC, and the organisms were enumerated after 48 h for Candida spp. and 72 h for Cryptococcus spp. The mean number of CFU per gram of tissue in the organs of the treated groups was compared with those in the organs from sham-treated control animals. Percent clearance indicates the number of mice in which there were no detectable yeasts and in which the limit of detection, because of the dilution scheme, was 50 yeast cells per brain, spleen, or pair of kidneys.
Statistical analyses. Each compound was analyzed separately with data that were pooled across experiments. The experiment-to-experiment variability was accounted for by the nature of the statistical methodology performed and the inclusion of data for the control group only for those experiments in which the compound was tested. In the disseminated aspergillosis model, the 90% effective doses (ED 90 s) were estimated by a robust probit method (22, 25) from the survival rates calculated at days 14, 21, and 28 after challenge. The technique of Kaplan and Meier (17) was used to estimate survival rates for each dose across the entire 28-day duration of the studies. Median survival times could then be determined, and the log-rank test (9) was performed to determine significant differences among compound dose groups in a pairwise manner. Adjustment for the multiplicity of these tests was made by the Bonferroni procedure. Comparisons were determined to be significant at the ␣ ϭ 0.05 level. In the disseminated candidiasis model, effective ED 50 s were estimated at days 7, 14, and 21 after challenge by the method of Knudson and Curtis (18) and are defined as the concentration of compound (in milligrams per kilogram) that protected 50% of the mice from lethal challenge. In the target organ assays, the analysis of variance test of dose-response relationships with single-degree-of-freedom contrasts was used. The mean log 10 number of yeast CFU per organ was compared with those in the organs of sham-treated controls by the Dunnett (11) multiple comparison procedure. Inverse regression was used to estimate the doses which reduced the numbers of CFU per organ by 90% compared with those in the organs of controls. L-733560 and L-705589 significantly prolonged the survival of infected mice at concentrations of Ն0.02 and 0.08 mg/kg of body weight, respectively, compared with the survival times of infected, sham-treated animals. L-733560 levels at or greater than 0.31 mg/kg resulted in Ն85% survival at day 28 after challenge. L-705589 at levels of Ն0.08 mg/kg resulted in 95% survival at day 28. AMB at concentrations of Ն0.025 mg/kg significantly prolonged survival and gave a survival value of 80% at day 28 when it was used at 0.39 mg/kg. L-731373 was less active than L-733560 and L-705589 against A. fumigatus. Estimates of the ED 90 s of L-733560, L-705589, L-731373, and AMB at day 28 after challenge were 0.48, 0.12, Ͼ20.0, and 0.36 mg/kg, respectively. ITZ was also tested and was found to be inactive in this assay (ED 50 , Ͼ100.0 mg/kg), which may be due to the metabolism of the drug in rodents (23) or its poor solubility in AV.
RESULTS

Efficacy
Efficacy in the disseminated candidiasis mouse survival model. L-733560 administered parenterally (i.p.), was the most active of the pneumocandins against an induced disseminated C. albicans infection in both immunocompetent CD-1 and CЈ5-deficient DBA/2N mice; at day 21 after challenge ED 50 s were 0.15 and 0.08 mg/kg, respectively ( Table 1 ). The efficacy of L-733560 was comparable to that of i.p. administered AMB (0.30 mg/kg), and it was two-to fourfold more active than L-705589 and L-731373. The azole antifungal agents KTZ and FCZ, which were administered p.o., were active in this model and protected mice from lethal challenge with C. albicans (Table 1) . However, ITZ was inactive (ED 50 , Ͼ80.0 mg/kg), as was the case in the aspergillosis mouse survival model (23) . L-733560 was also tested p.o. Although the ED 50 s were measurable, efficacy was reduced Ն300-fold compared with that of L-733560 given i.p. (Table 1) .
Efficacy in the disseminated candidiasis target organ assay. The pneumocandins, AMB, KTZ, and FCZ were tested for their activities in reducing recoverable yeasts from the kidneys of mice challenged i.v. with C. albicans. ED 90 s were estimated on the basis of a comparison of the mean log 10 CFU per gram of paired kidneys at day 7 after challenge in the groups treated with antifungal agents and that in sham-treated control groups. The data are given in Table 2 . AMB and the pneumocandins were the most active compounds in reducing the counts in kidneys. AMB and L-733560, the most active pneumocandin, had ED 90 s of 0.005 and 0.01 mg/kg, respectively, while L-705589 and L-731373 had ED 90 s of 0.05 and 0.03 mg/kg, respectively. Again, as seen in the survival assay, L-733560 had activity when it was administered p.o., but the ED was considerably greater (ED 90 , 13.3 mg/kg). FCZ was more active than KTZ in this model (ED 90 s, 0.39 to 1.56 versus 6.4 mg/kg, respectively). Even though FCZ reduced the number of recoverable yeasts from the kidneys when it was used at concentrations of Ͼ0.39 mg/kg, it did not sterilize C. albicans-infected kidneys at the concentrations tested (Table 3) . L-733560 and AMB sterilized the kidneys to a high degree when they were used at the higher dose levels (Ն0.08 mg/kg). Even orally administered L-733560 sterilized 73% of the mouse kidneys when it was used at 50 mg/kg (Table 3 ). The efficacy of L-733560 over time in the TOKA is shown in Fig. 2 . L-733560 rapidly cleared recoverable yeasts from the kidneys when it was used at concentrations of 0.09 and 0.375 mg/kg and the counts remained greater than 2 log 10 CFU/g of kidney lower than those in the controls for 21 days after challenge.
Efficacy in the disseminated cryptococcosis target organ assay. At day 7 after challenge, L-733560 and AMB were tested for their activities in reducing the number of recoverable yeasts from the brains and spleens of mice infected i.v. with C. neoformans. L-733560 at concentrations of up to 10 mg/kg was ineffective in reducing the counts in the organs, while AMB cleared 100% of the yeasts from the organs when it was used at 0.31 mg/kg (data not shown).
DISCUSSION
The pneumocandins, especially L-733560, appear to meet many of the requirements for a new therapeutic agent including activity against clinically relevant fungal species, good aqueous solubility, favorable bioavailability, and an acceptable therapeutic index (5) clinically relevant species of Candida, with L-733560 being the most potent (6, 24) . Growth inhibition kinetic studies against C. albicans demonstrated fungicidal activity, with a 99.9% reduction in growth by 3 to 5 h (6, 24). Although no evidence concerning the therapeutic potential of the pneumocandins used topically is presented here, this class of compounds has been shown to have in vivo efficacy in mouse models of oropharyngeal and gastrointestinal as well as vaginal candidiases (12, 14) . Even though the pneumocandins do not give MICs for Aspergillus species when they are tested by classic broth microdilution assays (6, 24) , these compounds have been shown to have profound morphological effects attributed to inhibition of 1,3-␤-D-glucan synthesis (19, 20) . These measurable morphological effects, termed the minimal effective concentration, appear to correlate well with the potent activities of L-733560 and L-705589 in our disseminated A. fumigatus infection model (1). L-733560 has also been shown to be highly effective in a pulmonary aspergillosis model in rats (7) . The improved efficacies of L-733560 and L-705589 appear to be the result of the substitution of an aminoethyl ether functionality at the ornithine (hemiaminal). L-731373, which lacks the aminoethyl ether group at this position, showed reduced efficacy compared with those of L-733560 and L-705589 both in vivo and in vitro in the minimal effective concentration assay.
L-733560 exhibited weak but measurable in vitro activity (minimum fungicidal concentrations, 16 to 32 g/ml) against clinical isolates of C. neoformans (6, 24) , which did not translate to efficacy in our in vivo model. L-733560 administered both parenterally and orally has been shown to exhibit potent in vivo activity against P. carinii cysts in an immunocompromised rat model (26) . Other lipopeptides have also been shown to have anti-Pneumocystis activity (3, 10, 26, 27) .
Preliminary mouse toxicity tests with the pneumocandins administered as a single i.v. bolus have shown favorable therapeutic indices (ratio of maximum tolerated dose to efficacy in a disseminated candidiasis survival model) (5) . Comparative pharmacokinetics with pneumocandins in mice and rhesus monkeys have shown good bioavailability. L-733560 had halflives of 5.95 and 11.8 h in mice and rhesus monkeys, respectively, (15) .
The potent activities of the water-soluble pneumocandins L-705589, L-731373, and L-733560 in murine models against A. fumigatus, C. albicans, and P. carinii combined with a low toxic potential and good bioavailability make the pneumocandins potentially attractive candidates for use in the treatment of opportunistic and secondary infections in immunocompromised patients.
